We are live on ! Find out more
ALLR

Allarity Therapeutics
ALLR

2 hedge funds and large institutions have $33.3K invested in Allarity Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

723% more capital invested

Capital invested by funds: $4.05K → $33.3K (+$29.3K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$71.3K
2
TRCT
Tower Research Capital (TRC)
New York
+$23.8K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$32
2
Morgan Stanley
Morgan Stanley
New York
-$7
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$23.9K +$71.3K +6 New
TRCT
2
Tower Research Capital (TRC)
New York
$9.43K +$23.8K +2 New
Wells Fargo
3
Wells Fargo
California
$33 – – –
Bank of America
4
Bank of America
North Carolina
– -$32 – –
Morgan Stanley
5
Morgan Stanley
New York
– -$7 – –

ALLR Hedge Fund Activity: Q2 2023 in Review

2 of the 6,372 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q2 2023, worth a combined $33.3K — up 723% from $4.05K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ALLR positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $71.3K. The largest seller was Bank of America, cutting an estimated $32.

  • 2 institutional investors held Allarity Therapeutics (ALLR) as of Q2 2023, up from 0 in Q1 2023.
  • Funds reported $33.3K of Allarity Therapeutics stock for Q2 2023, up 723% quarter-over-quarter.
  • 2 funds opened new Allarity Therapeutics positions in Q2 2023 and 0 closed out, a net change of +2 holders.
  • The largest Allarity Therapeutics buyer in Q2 2023 was UBS Group, an estimated $71.3K added.
  • The largest Allarity Therapeutics seller in Q2 2023 was Bank of America, an estimated $32 sold.

Based on aggregated 13F filings for Q2 2023.